TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28455173

Group type: EXPERIMENTAL
Intervention: Email reminders
Number of subjects: 2348

Group type: COMPARATOR
Intervention: No email reminders
Number of subjects: 2348
Study: 28455281

Group type: EXPERIMENTAL
Intervention: Phentermine/topiramate extended release (ER)
Number of subjects: 3040

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3040
Study: 28457013

Group type: EXPERIMENTAL
Intervention: e-health-based coagulation service (CS)
Number of subjects: 2318

Group type: COMPARATOR
Intervention: Regular medical care (RMC)
Number of subjects: 2318
Study: 28457485

Group type: EXPERIMENTAL
Intervention: Ketamine treatment
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo or baseline
Number of subjects: 51
Study: 28457953

Group type: EXPERIMENTAL
Intervention: IFN-α treatment (recombinant human IFN-α-2b injections administered subcutaneously 2 to 3 times per week for 6 months)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: IFN-α treatment
Number of subjects: 107
Study: 28458180

Group type: EXPERIMENTAL
Intervention: MCP-1 mRNA expression in AgP patients
Number of subjects: 215

Group type: COMPARATOR
Intervention: MCP-1 and CCR2 genotype distribution
Number of subjects: 215

Group type: COMPARATOR
Intervention: MCP-1 and CCR2 allele frequencies
Number of subjects: 215
Study: 28458770

Group type: EXPERIMENTAL
Intervention: Novel Herbal-based Cream
Number of subjects: 0
Study: 28459071

Group type: EXPERIMENTAL
Intervention: Low-Fat Plant-Based Diet Supplemented with Plant-Based Meal Replacements
Number of subjects: 0
Study: 28460039

Group type: EXPERIMENTAL
Intervention: Elevated high-sensitivity cardiac troponin T (hsTnT) levels (>14 ng/L)
Number of subjects: 2898

Group type: EXPERIMENTAL
Intervention: Detectable hsTnT levels (5-14 ng/L)
Number of subjects: 2898

Group type: COMPARATOR
Intervention: Undetectable hsTnT levels (<5 ng/L)
Number of subjects: 2898
Study: 28460066

Group type: EXPERIMENTAL
Intervention: Dovitinib
Number of subjects: 5
Study: 28460140

Group type: EXPERIMENTAL
Intervention: L-T4 treatment
Number of subjects: 140
Study: 28461298

Group type: EXPERIMENTAL
Intervention: Adult-onset asthma patients with <10 smoked pack-years (never- and ex-smokers)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Non-obstructive adult-onset asthma patients
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 188
Study: 28461396

Group type: EXPERIMENTAL
Intervention: Pembrolizumab, 200 mg IV every 2 weeks, pomalidomide 4 mg daily for 21 days, dexamethasone 40 mg weekly
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 48
Study: 28461706

Group type: EXPERIMENTAL
Intervention: Prophylaxis with famotidine
Number of subjects: 2229

Group type: EXPERIMENTAL
Intervention: Prophylaxis with pentoprazol
Number of subjects: 2229

Group type: COMPARATOR
Intervention: Non-modifiable factors
Number of subjects: 2229

Group type: COMPARATOR
Intervention: Modifiable factors
Number of subjects: 2229
Study: 28461752

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 109
Study: 28462685

Group type: EXPERIMENTAL
Intervention: Heat exposure at 35°C for up to 120 minutes
Number of subjects: 8
Study: 28464732

Group type: EXPERIMENTAL
Intervention: Probenecid (250 mg twice a day for 1 week, followed by 500 mg twice a day for 3 weeks)
Number of subjects: 20
Study: 28464817

Group type: EXPERIMENTAL
Intervention: Post-operative atrial fibrillation (poAF) group
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no poAF)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: eQTL analysis
Number of subjects: 62
Study: 28464828

Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam
Number of subjects: 2047
Study: 28464906

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant external beam radiotherapy (EBRT)
Number of subjects: 76
Study: 28465125

Group type: EXPERIMENTAL
Intervention: High intact protein intake
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Intact protein intake
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Total protein maximized with medical foods (MF)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Nutrition counselling
Number of subjects: 86
Study: 28465300

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg orally twice a day for 10 days
Number of subjects: 22

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg orally once a day for 10 days
Number of subjects: 22
Study: 28465311

Group type: EXPERIMENTAL
Intervention: HeartMate II support
Number of subjects: 200

Group type: COMPARATOR
Intervention: Optimal medical management
Number of subjects: 200
Study: 28465315

Group type: EXPERIMENTAL
Intervention: CHF5633 (synthetic surfactant)
Number of subjects: 40
Study: 28465370

Group type: EXPERIMENTAL
Intervention: Ramucirumab 6 mg/kg every 2 weeks
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ramucirumab 10 mg/kg every 3 weeks
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ramucirumab 8 mg/kg every 2 weeks
Number of subjects: 28
Study: 28465454

Group type: EXPERIMENTAL
Intervention: Remote foot-temperature monitoring system (thermometric foot mat)
Number of subjects: 132
Study: 28465694

Group type: EXPERIMENTAL
Intervention: Visual analogue scale (VAS)
Number of subjects: 42
Study: 28465824

Group type: EXPERIMENTAL
Intervention: Manual therapy according to the School of Manual Therapy Utrecht (MTU)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Physical therapy (PT)
Number of subjects: 181
Study: 28466461

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Conventional oxygen
Number of subjects: 155
Study: 28466557

Group type: EXPERIMENTAL
Intervention: Imatinib treatment in e14a2 patients
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Imatinib treatment in e13a2 patients
Number of subjects: 559
Study: 28466686

Group type: EXPERIMENTAL
Intervention: Pre-operative concomitant hyperfractionated radiotherapy (HART) with co-administration of 5-fluorouracil (5FU), total dose 42 Gy in 28 fractions of 1.5 Gy, two times daily.
Number of subjects: 51
Study: 28467527

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 821
Study: 28468687

Group type: EXPERIMENTAL
Intervention: Web-based computer-tailored intervention 'Start to Stand'
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Web-based computer-tailored intervention 'Start to Stand' with action planning
Number of subjects: 155
Study: 28468797

Group type: EXPERIMENTAL
Intervention: selinexor, 3 to 80 mg/m²
Number of subjects: 79
Study: 28468890

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 0
Study: 28468891

Group type: EXPERIMENTAL
Intervention: lipid-rich ready-to-use therapeutic food
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: phytase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: lipids
Number of subjects: 0

Group type: COMPARATOR
Intervention: maize-based meals fortified with micronutrient powders
Number of subjects: 0
Study: 28468895

Group type: EXPERIMENTAL
Intervention: Vitamin B-6 supplementation, dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study: 28468947

Group type: EXPERIMENTAL
Intervention: Intratumoral Injection
Number of subjects: 0
Study: 28469486

Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate with single dose of Calcium Gluconate (SBCG1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate with double dose of Calcium Gluconate (SBCG2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methylprednisolone (MP)
Number of subjects: 0
Study: 28469670

Group type: EXPERIMENTAL
Intervention: Tracheal intubation
Number of subjects: 0
Study: 28469697

Group type: EXPERIMENTAL
Intervention: Lamivudine
Number of subjects: 1225

Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir
Number of subjects: 1225
Study: 28470739

Group type: EXPERIMENTAL
Intervention: Vitamin D2
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control
Number of subjects: 16
Study: 28470815

Group type: EXPERIMENTAL
Intervention: EBR+GZR+RBV for 12 weeks
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: EBR+GZR+RBV for 18 weeks
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: On-treatment virologic failure
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Resistance-associated substitutions (RASs) at virologic failure
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Common RAS at virologic failure
Number of subjects: 41
Study: 28470856

Group type: EXPERIMENTAL
Intervention: Health Research for Development
Number of subjects: 52
Study: 28470994

Group type: EXPERIMENTAL
Intervention: Transradial access (TRA)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Transfemoral access (TFA)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Shared decision making (SDM)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Bleeding risk
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Length of hospitalization
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Mobilization
Number of subjects: 142
Study: 28471286

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICSs) adherence measured by a 4-item self-report questionnaire
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICSs) adherence measured by a single question (SQ)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICSs) adherence measured by medication possession ratio (MPR)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Factors associated with ICS adherence
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Perception of asthma severity and risk of death
Number of subjects: 319
Study: 28471445

Group type: EXPERIMENTAL
Intervention: Type H vessel identification, positive for CD31 and Endomucin
Number of subjects: 0
Study: 28471765

Group type: EXPERIMENTAL
Intervention: Long-term antiretroviral therapy (ART)
Number of subjects: 3313
Study: 28472039

Group type: EXPERIMENTAL
Intervention: Cytokeratin-18 (CK18)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Cytokeratin-18 (CK18) for F2 prediction
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Cytokeratin-18 (CK18) for advanced fibrosis (F3-4) prediction
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Cytokeratin-18 (CK18) among patients without hyperuricemia
Number of subjects: 76
Study: 28472067

Group type: EXPERIMENTAL
Intervention: MVA85A vaccine
Number of subjects: 36
Study: 28472325

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Liraglutide and Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Mercodia assay
Number of subjects: 51
Study: 28472366

Group type: EXPERIMENTAL
Intervention: Enzalutamide or abiraterone in chemotherapy-naïve patients
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Enzalutamide or abiraterone in post-docetaxel patients
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Enzalutamide in PREMIERE trial
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: AR mutations in post-docetaxel patients
Number of subjects: 265
Study: 28472437

Group type: EXPERIMENTAL
Intervention: Anamorelin 100 mg once daily
Number of subjects: 513

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 513
Study: 28472487

Group type: EXPERIMENTAL
Intervention: 11-oxygenated steroids (11OHA4, 11OHT, 11ketoT, 11ketoA4)
Number of subjects: 114

Group type: COMPARATOR
Intervention: 11OHA4, 11OHT, 11ketoT, 11ketoA4, PregS
Number of subjects: 114

Group type: COMPARATOR
Intervention: PregS, 17-hydroxypregnenolone sulfate
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Testosterone levels
Number of subjects: 114
Study: 28472509

Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ) 200 mg/m2 × 5/28 day for 6 cycles followed by myeloablative high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT).
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: HDC (thiotepa 250 mg/m2/day × 3 days, then busulfan 3.2 mg/kg/day × 3 days) followed by ASCT.
Number of subjects: 41
Study: 28472928

Group type: EXPERIMENTAL
Intervention: Counseling sessions
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Pre-adherence preparation
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Support groups
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Peer mentorship
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Patient navigation
Number of subjects: 512
Study: 28472957

Group type: EXPERIMENTAL
Intervention: SAR97276A (IM: 0.18 mg/kg; IV: 0.14 mg/kg)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: SAR97276A (3-day IM regimen)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: SAR97276A (0.5 mg/kg once daily for 3 days)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: SAR97276A (0.25 mg/kg twice daily for 3 days)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (control group)
Number of subjects: 113
Study: 28472974

Group type: EXPERIMENTAL
Intervention: Dual-chamber cardiac pacing 'on' with Closed Loop Stimulation
Number of subjects: 128

Group type: COMPARATOR
Intervention: Dual-chamber cardiac pacing 'off' (placebo)
Number of subjects: 128
Study: 28473128

Group type: EXPERIMENTAL
Intervention: Valve-in-valve TAVR
Number of subjects: 365
Study: 28473206

Group type: EXPERIMENTAL
Intervention: SYD985
Number of subjects: 10

Group type: COMPARATOR
Intervention: T-DM1
Number of subjects: 10
Study: 28473406

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 0
Study: 28473600

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28473851

Group type: EXPERIMENTAL
Intervention: Levothyroxine Replacement Therapy
Number of subjects: 0
Study: 28474366

Group type: EXPERIMENTAL
Intervention: Lanicemine (AZD6765) administered intravenously
Number of subjects: 191
Study: 28474980

Group type: EXPERIMENTAL
Intervention: No DVT prophylaxis (medical or mechanical) during or after surgery
Number of subjects: 100
Study: 28474985

Group type: EXPERIMENTAL
Intervention: Migraine with aura (MA+)
Number of subjects: 931

Group type: EXPERIMENTAL
Intervention: Migraine without aura (MA-)
Number of subjects: 931

Group type: COMPARATOR
Intervention: Healthy group (Control)
Number of subjects: 931
Study: 28475354

Group type: EXPERIMENTAL
Intervention: Infusion of glucose with insulin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition containing amino acids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infusion of amino acids in critically ill mice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunoneutralizing glucagon in critically ill mice
Number of subjects: 0
Study: 28475690

Group type: EXPERIMENTAL
Intervention: Avalus™ bioprosthesis
Number of subjects: 686
Study: 28475704

Group type: EXPERIMENTAL
Intervention: Foveal-sparing geographic atrophy (GA)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Foveal-sparing size >1.5 mm2
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Bridge size <400 μm
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Anatomic parameters
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Local regression curves
Number of subjects: 65
Study: 28475735

Group type: EXPERIMENTAL
Intervention: Later-generation fluoroquinolone (moxifloxacin or levofloxacin)
Number of subjects: 834

Group type: COMPARATOR
Intervention: Earlier-generation fluoroquinolone or no fluoroquinolone
Number of subjects: 834
Study: 28476102

Group type: EXPERIMENTAL
Intervention: Adapted Recent Life Changes Questionnaire (RLCQ)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Qualitative methodology and in-depth interviews
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Scaling exercise on the RLCQ
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Content and face validity exercises
Number of subjects: 200
Study: 28476111

Group type: EXPERIMENTAL
Intervention: Single use bronchoscope (Ambu® aScope)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional bronchoscope
Number of subjects: 60
Study: 28476136

Group type: EXPERIMENTAL
Intervention: Supervised group exercise twice weekly for 12 weeks
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard antenatal care
Number of subjects: 300
Study: 28476148

Group type: EXPERIMENTAL
Intervention: Supported Self-management (SSM) intervention for 2 months, delivered by primary care and social workers.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced treatment as usual (control group) with a leaflet about depression.
Number of subjects: 0
Study: 28476163

Group type: EXPERIMENTAL
Intervention: German version of the Tinnitus Functional Index (TFI)
Number of subjects: 264
Study: 28476275

Group type: EXPERIMENTAL
Intervention: Benzodiazepine users (BZD)
Number of subjects: 476

Group type: COMPARATOR
Intervention: Non-BZD users
Number of subjects: 476
Study: 28476440

Group type: COMPARATOR
Intervention: Intravenous rituximab (375 mg/m2)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Subcutaneous rituximab (375 mg/m2)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Intravenous rituximab
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Subcutaneous rituximab
Number of subjects: 410
Study: 28476756

Group type: EXPERIMENTAL
Intervention: Inhaled inorganic nitrite
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28476882

Group type: EXPERIMENTAL
Intervention: Usual walking speed
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: Traffic light timing based on walking speed
Number of subjects: 926
Study: 28476913

Group type: EXPERIMENTAL
Intervention: Immediate implant insertion
Number of subjects: 414

Group type: COMPARATOR
Intervention: Delayed implant insertion
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: PSA detected
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Age increase (1-year)
Number of subjects: 414
Study: 28476931

Group type: EXPERIMENTAL
Intervention: Genetic variant rs11014566 (G allele)
Number of subjects: 5870
Study: 28477061

Group type: EXPERIMENTAL
Intervention: Telaprevir in combination with peg-interferon and ribavirin (Peg-IFN/RBV)
Number of subjects: 46
Study: 28477280

Group type: EXPERIMENTAL
Intervention: Blood samples collected at arrival, 24, and 48 hours later for RNA gene expression analysis.
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Observational study design.
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Targeted evaluations and secondary prevention strategies initiated based on identified markers.
Number of subjects: 1000
Study: 28477794

Group type: EXPERIMENTAL
Intervention: Caesarean delivery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28477848

Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 28478128

Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: MoCA cutoff scores of 20 and 21
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: MoCA scores <20
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: C-IADL measures
Number of subjects: 148
Study: 28478485

Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (55 kBq/kg body weight every 4 weeks for up to six injections)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (initial single injection of 110 kBq/kg BW followed by up to five injections of 55 kBq/kg BW Q4W)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (overall treatment)
Number of subjects: 19
Study: 28478771

Group type: EXPERIMENTAL
Intervention: Cariprazine 3-9 mg/d
Number of subjects: 586
Study: 28479237

Group type: EXPERIMENTAL
Intervention: Sunitinib (1 year)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sorafenib (unspecified duration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional immunotherapy (interferon-α and high dose interleukin-2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vascular endothelial growth factor and mTOR inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (upcoming trials)
Number of subjects: 0
Study: 28480049

Group type: EXPERIMENTAL
Intervention: Ever smokers (female)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Every one cigarette/day increase in smoking intensity (female)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Higher smoking intensities (female)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Past smokers (male)
Number of subjects: 225
Study: 28480218

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Elastography Shear Wave Velocity
Number of subjects: 0
Study: 28480334

Group type: EXPERIMENTAL
Intervention: 4-valent HPV (4vHPV) vaccine
Number of subjects: 389

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 389
Study: 28480528

Group type: EXPERIMENTAL
Intervention: SLE without aPL (white women)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: SLE without aPL (African American women)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: SLE with aPL (whites)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: SLE with aPL (African Americans)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: SLE with aPL (Hispanics)
Number of subjects: 408
Study: 28481606

Group type: EXPERIMENTAL
Intervention: Substance use disorder/housing case management
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: VA emergency department services
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Inpatient services
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: VA primary care visits
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: VA mental health visits
Number of subjects: 181
Study: 28481639

Group type: EXPERIMENTAL
Intervention: Jacobian determinant (measure of local lung expansion and contraction with respiration)
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Percentage of normal voxels within each millimeter distance from emphysematous voxels (mechanically affected lung - MAL)
Number of subjects: 680
Study: 28482007

Group type: EXPERIMENTAL
Intervention: Low-calorie diet for 8 weeks followed by 6 months of ad libitum diet
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Changes in plasma concentrations of EGFL6, FSTL3, and CRYAB
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Baseline expression of ASPN and USP53
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Expression quantitative trait loci analysis
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Regulatory network involving TGF-β1
Number of subjects: 21